The global epigenetics market is projected to reach USD 1,605.7 Million by 2022 from an estimated USD 854.0 Million in 2017, at a CAGR of 13.5% during the forecast period.
The report "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022", The decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer are the major factors driving the growth of this market.
Browse 191 market tables and 37 figures spread through 230 pages and in-depth TOC on "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022"
Kits Segment Accounted for the Largest Share of the Global Market, by Product
On the basis of product, the kits segment accounted for the largest share of the global epigenetics market in 2016. This can be attributed to the fact that a large number of kits are used in various epigenetic techniques.
The rising prevalence of a number of diseases, increasing R&D spending, and increased government funding for life science research are the other factors expected to support market growth.
Among the Application Segments, Oncology Dominated the Global Epigenetics Market in 2016
Based on application, the oncology segment accounted for the largest share of the epigenetics market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.
DNA Methylation Segment Dominated the Epigenetics Market, by Technology in 2016
On the basis of technology, the epigenetics market is segmented into DNA methylation, histone modifications, and other technologies (includes non-coding RNA and chromatin remodeling). The DNA methylation segment accounted for the largest share of the global epigenetics market in 2016.
The large share of this segment is attributed to the increasing incidence of cancer and the ability of this technique to study different types of cancer with quality outcomes.
North America Dominated the Global Epigenetics Market in 2016
North America accounted for the largest share of the epigenetics market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the epigenetics market in North America.
The major players in the global epigenetics market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
For more information: